Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01223911 | A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis | PHASE2 | COMPLETED | 34 | — | — | Jan 1, 2011 | Feb 1, 2013 | Feb 9, 2017 | 16 | Czechia, Denmark +4 |
| NCT02151409 | Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects | PHASE1 | COMPLETED | 60 | — | — | Jun 1, 2008 | Oct 1, 2009 | Feb 9, 2017 | 1 | Netherlands |
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | PLACEBO_COMPARATOR | - |
| NNC 0151-0000-0000 i.v. | EXPERIMENTAL | Dose escalation trial |
| NNC 0151-0000-0000 s.c. | EXPERIMENTAL | Dose escalation trial |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NNC 0151-0000-0000 | DRUG | Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period |
| placebo | DRUG | Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period |
Inclusion Criteria: * CZ: Age between 18 and 65 years (both inclusive) * A diagnosis of rheumatoid arthritis of at least three months before entry in trial * Active rheumatoid arthritis (RA) * Subjects are on stable doses of methotrexate (up to and including 25 mg/week) for at least 4 weeks before ...